Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies

Background and Objective The interleukin-36 signalling pathway is associated with pathogenesis of a number of inflammatory diseases. Spesolimab is a selective, humanised, IgG1 antibody that targets the interleukin-36 receptor. We aimed to evaluate the pharmacokinetics, safety and tolerability of sin...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical pharmacokinetics Ročník 61; číslo 12; s. 1771 - 1787
Hlavní autori:	Joseph, David, Thoma, Christian, Haeufel, Thomas, Li, Xiujiang
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Cham Springer International Publishing 01.12.2022 Springer Nature B.V
Predmet:	Antibodies Cytokines Dermatitis Dose-Response Relationship, Drug Double-Blind Method Drug dosages Half-Life Healthy Volunteers Humans Inflammatory diseases Infusions, Intravenous Injections, Subcutaneous Internal Medicine Laboratories Medicine Medicine & Public Health Monoclonal antibodies NCT NCT02525679 NCT02852824 NCT03100903 NCT03123094 NCT03617835 Original Original Research Article Pathogenesis Pharmacokinetics Pharmacology Pharmacology/Toxicology Pharmacotherapy Plasma United States > US
ISSN:	0312-5963, 1179-1926, 1179-1926
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!